Multi-001 Nivolumab v6
Multi-002 Carboplatin and etoposide v1
Multi-003 Pembrolizumab v5
Multi-004 Atezolizumab v6
LUN-006 Pemetrexed v7
LUN-007 Cisplatin & Pemetrexed v7
LUN-024 Carboplatin & Pemetrexed v5
LUN-027 Crizotinib for ALK positive advanced NSCLC v5
LUN-029 Nintendanib (Vargatef) and Docetaxel for NSCLC v3
LUN-030 Ceritinib v2
LUN-031 Osimertinib v2
LUN-032 Pembrolizumab for previously treated metastatic NSCLC v2
LUN-034 Alectinib v2
LUN-035 Durvalumab v3
LUN-036 Pembrolizumab, Carboplatin & Pemetrexed followed by Maintenance Pembrolizumab and Pemetrexed v1 LUN-037 Pembrolizumab, Cisplatin & Pemetrexed followed by Maintenance Pembrolizumab and Pemetrexed v1
LUN-038 Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin (EAMs scheme) v1
LUN-039 Brigatinib v1 LUN-041 Atezolizumab, carboplatin and etoposide (EAMS) for SCLC v1
LUN-042 Dacomitinib v1
LUN-043 Pembrolizumab, carboplatin and paclitaxel v1
LUN-044 Lorlatinib v1
